An observational study in Cataract, sponsored by Alcon Research. Recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Alcon Research (part of Alcon) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Cataract by Alcon — 4 open to participants now, 6 under way, none of them phase 3. Cataract · Alcon.
Among the 116 studies in Cataract by Alcon, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2025, is one of 12 observational ones, and was the 109th registered.
1,633 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →4 of the 116 studies in Cataract by Alcon are open now, in 6 countries. Recruiting first, the newest first:
Alcon Research · Sites in Australia, India, Philippines
Ages 22+
Alcon Research · Sites in United States
Ages 22+
Alcon Research · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 90 across 477 observational studies indexed under Cataract.
Median enrollment 95 across the 104 interventional studies, 145 across the 12 observational. Of the 101 that completed or were terminated, 76 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
4 of the studies in Cataract by Alcon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317728Alcon ResearchClinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design | 2026-11 |
| NCT06987474Alcon ResearchCapella Scientia Development Study | 2027-05 |
| NCT07228091Alcon ResearchSurgical Procedure Efficiency Evaluation stuDy | 2027-06 |
| NCT07587138Alcon ResearchClinical Evaluation of a Novel Trifocal IOL | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 116 studies in Cataract by Alcon, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study involves collecting biometry and aberration data using the next generation biometer, Unity DX.
In this prospective, noninterventional, single-arm, unmasked, multicenter study, 4 different subject cohorts will be enrolled simultaneously to collect biometry and aberrometry data using Unity DX. This study will be conducted in the US, India, Spain, and the Philippines.
Subjects will be recruited from clinical sites located in India, Spain, and the Philippines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects/eyes previously implanted with an Alcon monofocal or multifocal presbyopia correcting IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Subjects/eyes with planned implantation of an Alcon monofocal or monofocal toric IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Subjects/eyes with with prior refractive surgery such as LASIK or PRK and planned implantation of an Alcon monofocal or monofocal toric IOL. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Subjects/eyes with keratoconus, a progressive cornea disorder. Measurements will be taken with Unity DX and SMARTCataract DX (SCDX) Biometer and either the IOLMaster 700 Biometer or the Argos with Alcon Image Guidance Biometer depending on which device is used at site.
Device: Unity DX and SMARTCataract DX (SCDX) Biometer · Device: IOLMaster 700 Biometer · Device: Argos with Alcon Image Guidance Biometer
Unity DX is a CE-marked, noninvasive, noncontact instrument that generates a 3D model of the eye using hyper parallel optical coherence tomography (HP OCT), aberrometry, and topography. The current version of SCDX software will be used in this study.
The IOLMaster 700 Biometer is a CE-marked, noninvasive, noncontact instrument that captures optical biometry. Data will be collected using standard clinical assessments.
The Argos with Alcon Image Guidance biometer is a CE-marked, noninvasive, noncontact instrument that will capture optical biometry. Data will be collected using standard clinical assessments.
Manifest Refraction Spherical Equivalent (MRSE)
A manifest refraction (manual refraction) will be performed using a phoropter. The spherical equivalent is calculated by adding the sum of the sphere power with half of the cylinder power. MRSE will be reported in diopters.
Time frame: Group 1 and Group 4: Day 0; Group 2 and Group 3: Screening (Day -30 to Day -1), Day 30 to 60 postoperative, Day 70 to 100 postoperative
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.
Of 67 industry-sponsored observational studies under Cataract, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 22 months is above that.
Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.